An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide

Cancer Immunity

Volumn 13, Issue 3, 2013, Pages

  Hardwick, Nicola ^a   Buchan, Sarah ^b   Ingram, Wendy ^a   Khan, Ghazala ^c   Vittes, Gisella ^b   Rice, Jason ^b   Pulford, Karen ^d   Mufti, Ghulam ^a   Stevenson, Freda ^b   Guinn, Barbara Ann ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acute myeloid leukemia; Analogue peptide; DNA vaccine; Immunotherapy; PASD1

Indexed keywords

CANCER TESTIS ANTIGEN; DNA VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PA14 PEPTIDE; PEPTIDE DERIVATIVE; PROTEIN PASD1; UNCLASSIFIED DRUG; CANCER VACCINE; CELL NUCLEUS ANTIGEN; EPITOPE; PASD1 PROTEIN, HUMAN; PEPTIDE; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY TEST; DRUG DESIGN; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROCESSING; SPLEEN CELL; WILD TYPE; ANALOGUE PEPTIDE; ANIMAL; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; PASD1;

ACUTE MYELOID LEUKEMIA; ANALOGUE PEPTIDE; DNA VACCINE; IMMUNOTHERAPY; PASD1;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES; HUMANS; IMMUNOTHERAPY; MALE; MICE; PEPTIDES;

EID: 84880160266     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1. (PMID: 14738373)
2. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carn-inci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, Hide W. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 2008; 105: 20422-20427. (PMID: 19088187)
3. Chambost H, Brasseur F, Coulie P, de Plaen E, Stoppa AM, Baume D, Mannoni P, Boon T, Maraninchi D, Olive D. A tumour-associ-ated antigen expression in human haematological malignancies. Br J Haematol 1993; 84: 524-526. (PMID: 8217804)
4. Chambost H, Collette Y, Dutartre H, Thuret I, Olive D. Parameters involved in the recognition of fresh human leukemic blasts by tumor-specific cytolytic T cell clones: a model study. Leuk Res 2000; 24: 823-830. (PMID: 10996200)
5. Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, Guinn B. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukaemia 2002; 16: 2238-2242. (PMID: 12399967)
6. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002; 188: 43-50. (PMID: 12445280)
7. Guinn BA, Collin JF, Li G, Rees RC, Mufti GJ. Optimised SEREX technique for the identification of leukaemia-associated antigens. J Immunol Methods 2002; 264: 207-214. (PMID: 12191523)
8. Liggins AP, Guinn BA, Banham AH. Identification of lymphoma-associated antigens using SEREX. Methods Mol Med 2005; 115: 109-128. (PMID: 15122589)
9. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ. Humoral detection of leukaemia-asso-ciated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 335: 1293-1304. (PMID: 16112646)
10. Liggins AP, Guinn BA, Hatton CS, Pulford K, Banham AH. Sero-logic detection of diffuse large B-cell lymphoma-associated anti-gens. Int J Cancer 2004; 110: 563-569. (PMID: 15122589)
11. Liggins AP, Brown PJ, Asker K, Pulford K, Banham AH. A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 2004; 91: 141-149. (PMID: 15162151)
12. Cooper CD, Liggins AP, Ait-Tahar K, Roncador G, Banham AH, Pulford K. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukaemia 2006; 20: 2172-2174. (PMID: 17024112)
13. Sahota SS, Goonewardena CM, Cooper CD, Liggins AP, Ait-Tahar K, Zojer N, Stevenson FK, Banham AH, Pulford K. PASD1 is a potential multiple myeloma-associated antigen. Blood 2006; 108: 3953-3955. (PMID: 17114574)
14. Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C, Moir D, Hatton C, Banham AH, Pulford K. Cytolytic T cell response to the PASD1 cancer testis antigen in patients with dif-fuse large B-cell lymphoma. Br J Haematol 2009; 146: 396-407. (PMID: 19552722)
15. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Döhner H, Schmitt M. mRNA expression of leukaemia-associated antigens in patients with acute myeloid leukaemia for the develop-ment of specific immunotherapies. Int J Cancer 2004; 108: 704-711. (PMID: 14696097)
16. Guinn BA, Gilkes AF, Woodward E, Westwood NB, Mufti GJ, Linch D, Burnett AK, Mills KI. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Bio-phys Res Commun 2005; 333: 703-713. (PMID: 15963951)
17. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Can-cer 2008; 8: 108-120. (PMID: 18219306)
18. Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized reper-toire. J Immunol 2004; 173: 4492-4499. (PMID: 15383580)
19. Rice J, Buchan S, Stevenson FK. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol 2002; 169: 3908-3913. (PMID: 12244189)
20. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T cell responses and increases PSA dou-bling time. Cancer Immunol Immunother 2012; 61: 2161-2170. (PMID: 22729556)
21. Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf RM, Sami M, Boulter JM, Rizkal-lah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK, Griffiths G, Jones EY, Cerundolo V. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 2005; 201: 1243-1255. (PMID: 15837811)
22. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Enhanced induction of human WT1-spe-cific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-620. (PMID: 12439606)
23. Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhal-eva V, Zhang RH, Scheinberg DA. Improved human T cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukaemia 2006; 20: 2025-2033. (PMID: 16990779)
24. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in mela-noma patients. J Immunother 2008; 31: 781-791. (PMID: 18779741)
25. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T cell responses. Haemato-logica 2005; 90: 1324-1332. (PMID: 16219568)
26. May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recog-nize and kill human malignant mesothelioma tumor cells. Clin Can-cer Res 2007; 13: 4547-4555. (PMID: 17671141)
27. Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Gold-schmidt H, Klein B, Hundemer M. Melan-A/MART1 analog pep-tide triggers anti-myeloma T cells through crossreactivity with HM1.24. J Immunother 2009; 32: 613-621. (PMID: 19483648)
28. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E, Scheinberg DA. A pilot vac-cination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukaemia 2008; 22: 1613-1616. (PMID: 18256684)
29. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukaemia. Blood 2010; 116: 171-179. (PMID: 20400682)
30. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ. Ex vivo char-acterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leu-kaemia and acute and chronic myeloid leukaemia. Blood 2009; 113: 2245-2255. (PMID: 18988867)
31. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichi-ello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lym-phocytes specific for a new PRAME-derived peptide can target leu-kemic and leukemic-precursor cells. Blood 2011; 117: 3353-3362. (PMID: 21278353)
32. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukaemia shapes host immunity by selective deletion of high-avidity leukaemia-specific T cells. J Clin Invest 2003; 111: 639-647. (PMID: 12618518)
33. Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sund-berg B, Gerbitz A, Ljungman P, Le Blanc K. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukaemia 2013; 27: 377-388. (PMID: 22828446)
34. Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukaemia 2008; 22: 1084-1087. (PMID: 17972945)
35. Wendelbo Ø, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud Ø. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukaemia and chemotherapy-induced leu-kopenia. Cancer Immunol Immunother 2004; 53: 740-747. (PMID: 15133630)
36. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008; 112: 2956-2964. (PMID: 18502835)
37. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 1281-1286. (PMID: 9809552)
38. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisser-enc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Steven-son F, Charron D, Chomienne C. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukae-mia. Nat Med 2003; 9: 1413-1417. (PMID: 14566333)
39. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219. (PMID: 10602881)
40. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of indi-vidual peptide side-chains. J Immunol 1994; 152: 163-175. (PMID: 8254189)
41. Demotz S, Matricardi P, Lanzavecchia A, Corradin G. A novel and simple procedure for determining T cell epitopes in protein anti-gens. J Immunol Methods 1989; 122: 67-72. (PMID: 2474615)
42. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cyto-toxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987; 326: 881-882. (PMID: 2437457)
43. Bodinier M, Peyrat MA, Tournay C, Davodeau F, Romagne F, Bonneville M, Lang F. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and pep-tide with reduced CD8 binding. Nat Med 2000; 6: 707-710. (PMID: 10835691)
44. Hosken NA, Bevan MJ. Defective presentation of endogenous anti-gen by a cell line expressing class I molecules. Science 1990; 248: 367-370. (PMID: 2326647)
45. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined pep-tide motifs: implications for cancer vaccines. J Immunol 2001; 167: 1558-1565. (PMID: 11466377)
46. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 mono-chain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185: 2043-2051. (PMID: 9182675)
47. Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vacci-nation against a tumor antigen. J Immunol 2005; 174: 6292-6298. (PMID: 15879128)
48. Rice J, King CA, Spellerberg MB, Fairweather N, Stevenson FK. Manipulation of pathogen-derived genes to influence antigen pre-sentation via DNA vaccines. Vaccine 1999; 17: 3030-3038. (PMID: 10462238)